Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Alimta (Pemetrexed) in Patients With Recurrent Malignant Gliomas, Primary Central Nervous System Lymphoma, and Brain Metastases

NCT00276783 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT00276783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00276783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Alimta (Pemetrexed) in Patients With Recurrent Malignant Gliomas, Primary Central Nervous System Lymphoma, and Brain Metastases
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2005
Completion date
December 31, 2022
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, lymphoma, metastatic cancer